CN119604496A - Rock2抑制剂 - Google Patents

Rock2抑制剂 Download PDF

Info

Publication number
CN119604496A
CN119604496A CN202380050515.XA CN202380050515A CN119604496A CN 119604496 A CN119604496 A CN 119604496A CN 202380050515 A CN202380050515 A CN 202380050515A CN 119604496 A CN119604496 A CN 119604496A
Authority
CN
China
Prior art keywords
alkyl
group
alkynyl
alkenyl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380050515.XA
Other languages
English (en)
Chinese (zh)
Inventor
S·D·瓦克萨尔
A·扎宁-佐洛夫
G·卡奇科夫斯基
M·索卢奇
A·杰德泽扎克
M·克尔瓦纳
D·多玛加拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Greweton Biotechnology Co ltd
Original Assignee
Greweton Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Greweton Biotechnology Co ltd filed Critical Greweton Biotechnology Co ltd
Publication of CN119604496A publication Critical patent/CN119604496A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202380050515.XA 2022-04-29 2023-04-29 Rock2抑制剂 Pending CN119604496A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263336667P 2022-04-29 2022-04-29
US63/336667 2022-04-29
PCT/IB2023/054494 WO2023209692A1 (en) 2022-04-29 2023-04-29 Inhibitors of rock2

Publications (1)

Publication Number Publication Date
CN119604496A true CN119604496A (zh) 2025-03-11

Family

ID=86604437

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380050515.XA Pending CN119604496A (zh) 2022-04-29 2023-04-29 Rock2抑制剂

Country Status (9)

Country Link
US (1) US20250289807A1 (enExample)
EP (1) EP4514466A1 (enExample)
JP (1) JP2025514382A (enExample)
KR (1) KR20250019030A (enExample)
CN (1) CN119604496A (enExample)
AU (1) AU2023262720A1 (enExample)
CA (1) CA3250707A1 (enExample)
IL (1) IL316616A (enExample)
WO (1) WO2023209692A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120204259A (zh) * 2025-04-17 2025-06-27 江西省肿瘤医院(江西省第二人民医院、江西省癌症中心) Rock2抑制剂及其在制备治疗胆管癌的药物中的应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026502949A (ja) 2022-12-30 2026-01-27 アヴィセンナ バイオサイエンシズ インコーポレイテッド アザインドールｒｏｃｋ阻害剤
IL327381A (en) 2023-09-28 2026-05-01 Graviton Pharmaceuticals B V Treatment for type 1 diabetes using ROCK2 and DYRK1 inhibitors
IL327385A (en) 2023-09-29 2026-05-01 Graviton Pharmaceuticals B V ROCK2 inhibitors in the treatment of obesity
WO2026011129A1 (en) * 2024-07-03 2026-01-08 Avicenna Biosciences, Inc. Azaindole rock inhibitors for the treatment of medical disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7311228B2 (ja) 2017-06-30 2023-07-19 ベイジン タイド ファーマシューティカル カンパニー リミテッド Ｒｈｏ－関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用
JP7399848B2 (ja) * 2017-09-01 2023-12-18 カドモン コーポレイション，リミティド ライアビリティ カンパニー Ｒｈｏ関連コイルドコイル含有プロテインキナーゼの阻害剤

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120204259A (zh) * 2025-04-17 2025-06-27 江西省肿瘤医院(江西省第二人民医院、江西省癌症中心) Rock2抑制剂及其在制备治疗胆管癌的药物中的应用

Also Published As

Publication number Publication date
WO2023209692A1 (en) 2023-11-02
JP2025514382A (ja) 2025-05-02
KR20250019030A (ko) 2025-02-07
US20250289807A1 (en) 2025-09-18
CA3250707A1 (en) 2023-11-02
IL316616A (en) 2024-12-01
AU2023262720A1 (en) 2024-12-12
EP4514466A1 (en) 2025-03-05

Similar Documents

Publication Publication Date Title
CN111989332B (zh) 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用
EP3584239B1 (en) O-aminoheteroaryl alkynyl-containing compound, preparation method therefor, and use thereof
AU2024200901A1 (en) Compositions and Methods using the same for Treatment of Neurodegenerative and Mitochondrial Disease
EP2978752B1 (en) 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide derivatives and their use as phd inhibitors
US20250289807A1 (en) Inhibitors of ROCK2
CN118055933B (zh) 选择性parp1抑制剂及其应用
CN117143107A (zh) 1,2-二氢吡啶类衍生物及其制备方法和用途
CN116867784A (zh) 吡啶衍生物及其在医药上的应用
CN120882712A (zh) Rock2抑制剂
WO2014086102A1 (zh) 作为酪氨酸激酶抑制剂的吲哚满酮衍生物
KR20180114057A (ko) 피리미딘 7-원 고리 화합물, 이의 제조 방법, 이의 약제학적 조성물, 및 이의 용도
EP3418277B1 (en) Substituted amino six-membered nitric heterocyclic ring compound and preparation and use thereof
CN115803085A (zh) 新型细胞代谢调节化合物及用途
JP2020517654A (ja) ジヒドロオロト酸オキシゲナーゼの阻害剤としての三置換ベンゾトリアゾール誘導体の使用方法
KR101746199B1 (ko) 질소 함유 헤테로아릴 유도체 및 GSK3β 저해제로서의 이의 용도
JP7110335B2 (ja) プロテインキナーゼ阻害剤として有用なピリドキナゾリン誘導体
CN104884456B (zh) PI3K和/或mTOR抑制剂
CN116535423B (zh) 抑制/诱导降解egfr激酶的化合物及其药物组合物和应用
CN111377906B (zh) 取代的吡嗪化合物及其制备方法和用途
CN121226329A (zh) 一种治疗或预防lrrk2介导的疾病的化合物
EP4608509A1 (en) New inhibitors of phosphatidylinositol 3-kinase
CN117843566A (zh) 多取代苯衍生物及其组合物和用途
BR112019024892B1 (pt) Inibidores da proteína quinase
BR112018016264B1 (pt) Composto de anel heterocíclico nítrico de seis membros substituído por amino e preparação e uso do mesmo

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination